Medical Oncology

Doç. Dr. Esra Zeynelgil

Doctor and researcher Ankara Etlik Şehir Hastanesi Ankara
Lung NeoplasmsCarcinoma, Non-Small-Cell LungAdenocarcinoma, Mucinous
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Lung Neoplasms 6 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Carcinoma, Non-Small-Cell Lung 3 publications
  • Adenocarcinoma, Mucinous 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionAnkara Etlik Şehir Hastanesisaglik.gov.trFrom source
  • Area of workLung NeoplasmsExtracted from 6 publications · Model version —From source
  • Publications53 publicationsOpenAlex, ORCID, Europe PMCFrom source
  • ORCID0000-0001-7200-9440ORCIDFrom source
  • Last synchronised7 November 2026 00:02https://etliksehir.saglik.gov.tr/TR-864408/klinik-doktorlarimiz.html#esra-zeynelgilsaglik.gov.tr

Scientific work

Publications on Lung Neoplasms

53 publications

  1. Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15725-9 PMID 41691201 Open-access full textSource: OpenAlex

  2. Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

    Clinical & Translational Oncology, 2026

    DOI 10.1007/s12094-026-04494-3 PMID 42400766 Source: OpenAlex

  3. Meme Kanseri

    Akademisyen Kitabevi eBooks, 2026

    DOI 10.37609/akya.3852 Open-access full textSource: OpenAlex

  4. Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis

    The oncologist, 2026

    DOI 10.1093/oncolo/oyag092 PMID 41838398 Open-access full textSource: ORCID

  5. Serum Vitamin D as a Predictor of Immunotherapy Response in Advanced Non-small Cell Lung Cancer

    Acta haematologica oncologica Turcica., 2026

    DOI 10.4274/ahot.galenos.2026.2026-4-7 Open-access full textSource: OpenAlex

  6. Impact of Prior mRNA COVID-19 Vaccination on PFS2 in NSCLC Patients Receiving Second-Line Immune Checkpoint Inhibitors: A Real-World Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15072475 PMID 41976774 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  7. Prognostic Significance of Lung Immune Prognostic Index at Diagnosis in Stage III Non-Small Cell Lung Cancer

    Current oncology (Toronto, Ont.), 2026

    DOI 10.3390/curroncol33010043 PMID 41590363 1 citation (Europe PMC) Open-access full textSource: Europe PMC

  8. Association Between Smoking Status and PD-L1 Expression in Metastatic Driver Mutation Negative Non-Small Cell Lung Cancer: A Real-World Cohort Study

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.2612473 Source: OpenAlex

  9. Independent factors associated with advanced testicular germ cell tumors: the roles of smoking, lymphovascular invasion, and tumor size

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15598-y PMID 41555284 Open-access full textSource: OpenAlex

  10. Emergency Surgery Independently Predicts Postoperative Recurrence in Patients with Pathologic T3N0M0 Colon Cancer: A Retrospective Single-Center Cohort Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33090526 PMID 42782872 Open-access full textSource: OpenAlex

View all 53 publications